Biocon founder and chairperson Kiran Mazumdar-Shaw’s recent announcement of a phased, five-year succession plan, involving naming her niece, Claire Mazumdar, as her successor, marked a pivotal generational leadership shift for the enterprise she founded in 1978 in Bengaluru and eventually emerged as a bellwether of the Indian biotechnology industry.

The succession announcement came alongside a significant corporate restructuring at Biocon, including the merger of its generics and biologics businesses under a single platform. Biocon had earlier said that by March 31, 2026, it would be integrating its generics and biosimilars businesses into a unified global biopharma platform to accelerate growth, simplify its structure, and streamline its product offerings. This move was aimed at consolidating Biocon Biologics into the parent company, increasing the focus on diabetes, oncology, and immunology. Other areas of Mazumdar-Shaw’s focus included: cancer therapeutics, biologics, immunotherapy, novel drug discovery, and affordable insulin and diabetes care, apart from nanotechnology, precision medicine and translational research.

As a precursor to the gradual succession plan, Mazumdar-Shaw appointed Shreehas Tambe as CEO and Managing Director in April 2026 to strengthen leadership at Biocon during the transition. While maintaining a strategic vision and ensuring close family presence in the business, through niece, Claire.

It may be recalled that the Bengaluru-based biotech entrepreneur in an X post indicated that her niece, was expected to eventually take over as chairperson of Biocon, and she was preparing for a gradual leadership transition plan that would roll for the next five years. Thirty-seven-year-old Claire, is currently the founding chief executive of Bicara Therapeutics, a Nasdaq-listed, biotech firm incubated by Biocon. She is the daughter of Ravi Mazumdar, brother of Kiran Mazumdar-Shaw, and Catherine Rosenberg. Claire holds degrees from Massachusetts Institute of Technology and Stanford University, including a PhD in cancer biology.

According to industry observers, Mazumdar-Shaw’s move towards leadership transition would certainly have broader implications for the biotech industry, a space that she invented, dominated and has led as well.

Brewing to biotech

Rasendra Mazumdar, a brewmaster at United Breweries, introduced his daughter, Kiran, to fermentation science, quite a strange career choice for Indian women in the 1970s. After the completion of malting and brewing courses in Australia, she returned to India to discover breweries were not hiring woman brewmasters.

The seed for Biocon started evolving from this experience and in 1978, at 25, in partnership with Ireland’s Biocon Biochemicals, she started Biocon in her garage in Bengaluru with a modest initial capital of just ₹10,000.

Even during the late ’90s, no media person who met her missed her stories about her entrepreneurial struggles for capital, bank loans and permissions. Banks were reluctant to lend to women entrepreneurs back then. However, later on, she became successful through lobbying with the Karnataka government and receiving KIADB land to set up Biocon ventures, research infrastructure, Biocon Park, healthcare infrastructure etc. She also runs the Mazumdar Shaw Cancer Center in Bengaluru.

She has tried hard to convince successive governments in the State to make them understand how biotechnology as an industry was unique, unlike IT, and required long-term thinking and quality infrastructure for research for it to take off.

Mazumdar-Shaw’s start-up venture Biocon, after multiple decades of struggle, has truly emerged as the country’s bellwether of the biotechnology industry and became a global player in biosimilars manufacturing.

Under Kiran’s leadership, Biocon evolved in phases from enzymes and fermentation capabilities in the 1980s and ‘90s, biopharmaceuticals, insulin, statins and novel biologics in 2000s, biosimilars, oncology and advanced biologics from 2010 onwards.

Biocon today claims to be the leading global biosimilars company, with over 30 biosimilars and 12 commercially launched products across insulin, oncology and immunology in the U.S., Europe and other markets.

Biocon triggered a bioeconomy boom in Karnataka. Indeed, Mazumdar-Shaw’s outspoken nature and relentless advocacy for biocon and biotechnology industry has also helped Bengaluru emerge as a significant biotech hub. She has been a member of the State’s Vision Group on Biotechnology.

According to the State’s IT and BT Minister Priyank Kharge, Karnataka’s bioeconomy is valued at $39.2 billion as of March 2026, representing about 21% of India’s total bioeconomy and contributes over 10% to the State’s Gross State Domestic Product (GSDP). The state’s bioeconomy grew by 26.5% between 2023 and 2025 and it is adding nearly $10 billion every quarter to the State’s economy.

Karnataka has an ambitious target of growing its bio-economy to $100 billion by 2030. To achieve this, the sector needs a Compounded Annual Growth Rate of 19%, said minister Kharge.

Fourth quarter results

Biocon on Thursday reported a sharp year-on-year fall of 63% in its fourth-quarter net profit to Rs. 126 crore.

It said, despite growth in core businesses, the company incurred an exceptional charge of Rs. 80 crore in Q4 towards business integration and included the impact of the new labour codes.